The Latest Cardiac and Vascular News
CARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023. Recent Highlights: Reported revenue of $4.2 million for the […]
– Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma – – Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients – – Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., May […]
— New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit — — First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty in Japan — — Conference call scheduled for 8:30 a.m. ET today — MIAMI, May […]
Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 million BackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation in the second half of 2023 in collaboration with Medtronic Virtue SAB® U.S. pivotal study in coronary in-stent restenosis (“ISR”) start planned for […]
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint China National Medical Products Administration (NMPA) accepted mavacamten New Drug Application (NDA) with priority review Mavacamten commercial launch preparations continue in China, supported by the promotion of Pascal Qian to Chief Commercial Official Cash, cash equivalents […]
Closed $26.5 Million with a Public Offering and Registered Direct Offering to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones and Extend Cash Runway into Late 2024 Strategic Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Management to Host Webcast […]
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced financial results for the first quarter ended March 31, 2023. Business Updates Announced the appointment of Gansevoort “Gan” Dunnington, MD, as Chief […]
The company confirms its sales target of €10-13 million for 2023 PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure, informs its shareholders that the Combined General […]
2023 Q1 highlights: Revenue was $18.2 million, an increase of 30% compared to the corresponding period of 2022 Net income was $5.0 million, an increase of 48% compared to the corresponding period of 2022 Cash, cash equivalents and short-term investments of $43.0 million SANTA CLARA, Calif., May 10, 2023 /PRNewswire/ — Semler Scientific, Inc. (Nasdaq: SMLR), […]
DENVER, May 10, 2023 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) (the “Company”) today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the […]
